Histone deacetylase inhibitors reinforce the phenotypical markers of breast epithelial or mesenchymal cancer cells but inhibit their migratory properties

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Makki J. Diversity of breast carcinoma: histological subtypes and clinical relevance. Clin Med Insights Pathol. 2015;8:23–31. doi:10.4137/CPath.S3156326740749
   PubMed Web of Science ®Google Scholar
• Rivenbark AG, O’Connor SM, Coleman WB. Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. Am J Pathol. 2013;183(4):1113–1124. doi:10.1016/j.ajpath.2013.08.00223993780
   PubMed Web of Science ®Google Scholar
• Zhang MH, Man HT, Zhao XD, Dong N, Ma SL. Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review). Biomed Reports. 2014;2(1):41–52. doi:10.3892/br.2013.187
   PubMedGoogle Scholar
• Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. doi:10.1038/3502109310963602
   PubMed Web of Science ®Google Scholar
• Sethi S, Sarkar FH, Ahmed Q, et al. Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma. Transl Oncol. 2011;4(4):222–226. http://www.ncbi.nlm.nih.gov/pubmed/21804917. Accessed, 2019.21804917
   PubMed Web of Science ®Google Scholar
• Adamo B, Ricciardi GRR, Ieni A, et al. The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer. Oncotarget. 2017;8(44):76974–76986. doi:10.18632/oncotarget.2029329100362
   PubMedGoogle Scholar
• Fedele P, Orlando L, Cinieri S. Targeting triple negative breast cancer with histone deacetylase inhibitors. Expert Opin Investig Drugs. 2017;26(11):1199–1206. doi:10.1080/13543784.2017.1386172
   PubMed Web of Science ®Google Scholar
• Falahi F, van Kruchten M, Martinet N, Hospers G, Rots MG. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer. Breast Cancer Res. 2014;16(4):412. doi:10.1186/s13058-014-0412-z25410383
   PubMed Web of Science ®Google Scholar
• Guo P, Chen W, Li H, Li M, Li L. The histone acetylation modifications of breast cancer and their therapeutic implications. Pathol Oncol Res. 2018;24(4):807–813. doi:10.1007/s12253-018-0433-529948617
   PubMed Web of Science ®Google Scholar
• Wawruszak A, Kalafut J, Okon E, et al. Histone deacetylase inhibitors and phenotypical transformation of cancer cells. Cancers (Basel). 2019;11(2):148. doi:10.3390/cancers11020148
   PubMed Web of Science ®Google Scholar
• Mrakovcic M, Bohner L, Hanisch M, Fröhlich LF. Epigenetic targeting of autophagy via HDAC inhibition in tumor cells: role of p53. Int J Mol Sci. 2018;19(12):3952. doi:10.3390/ijms19123952
   PubMed Web of Science ®Google Scholar
• Shah RR. Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology. Drug Saf. 2019. doi:10.1007/s40264-018-0773-9
   Web of Science ®Google Scholar
• Heerboth S, Housman G, Leary M, et al. EMT and tumor metastasis. Clin Transl Med. 2015;4:6. doi:10.1186/s40169-015-0048-325852822
   PubMed Web of Science ®Google Scholar
• Santamaria PG, Moreno-Bueno G, Portillo F, Cano A. EMT: present and future in clinical oncology. Mol Oncol. 2017;11(7):718–738. doi:10.1002/1878-0261.1209128590039
   PubMed Web of Science ®Google Scholar
• Lacerda L, Debeb BG, Smith D, et al. Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model. Breast Cancer Res. 2015;17(1):42. doi:10.1186/s13058-015-0549-425887413
   PubMedGoogle Scholar
• Kendall K. Cell adhesion century: culture breakthrough. Philos Trans R Soc B Biol Sci. 2014;370(1661):20140025. doi:10.1098/rstb.2014.0025
   Web of Science ®Google Scholar
• Blaschuk OW. N-cadherin antagonists as oncology therapeutics. Philos Trans R Soc B Biol Sci. 2014;370(1661):20140039. doi:10.1098/rstb.2014.0039
   Web of Science ®Google Scholar
• Luo Y, Yu T, Zhang Q, et al. Upregulated N-cadherin expression is associated with poor prognosis in epithelial-derived solid tumours: A meta-analysis. Eur J Clin Invest. 2018;48(4). doi:10.1111/eci.12903
   PubMed Web of Science ®Google Scholar
• Nalls D, Tang S-N, Rodova M, Srivastava RK, Shankar S. Targeting epigenetic regulation of mir-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. Batra SK, ed. PLoS One. 2011;6(8):e24099. doi:10.1371/journal.pone.002409921909380
   PubMed Web of Science ®Google Scholar
• Mateen S, Raina K, Agarwal C, Chan D, Agarwal R. Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating e-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells. J Pharmacol Exp Ther. 2013;345(2):206–214. doi:10.1124/jpet.113.20347123461975
   PubMed Web of Science ®Google Scholar
• Shah P, Gau Y, Sabnis G. Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin. Breast Cancer Res Treat. 2014;143(1):99–111. doi:10.1007/s10549-013-2784-724305977
   PubMed Web of Science ®Google Scholar
• Wang JH, Lee EJ, Ji M, Park SM. HDAC inhibitors, trichostatin A and valproic acid, increase E‑cadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells. Oncol Rep. 2018;40(1):346–354. doi:10.3892/or.2018.644129767267
   PubMed Web of Science ®Google Scholar
• Wawruszak A, Luszczki JJ, Grabarska A, et al. Assessment of interactions between cisplatin and two histone deacetylase inhibitors in MCF7, T47D and MDA-MB-231 human breast cancer cell lines – an isobolographic analysis. Asselin E, ed. PLoS One. 2015;10(11):e0143013. doi:10.1371/journal.pone.014301326580554
   PubMed Web of Science ®Google Scholar
• Chiu H-W, Yeh Y-L, Wang Y-C, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo. Agoulnik IU, ed. PLoS One. 2013;8(10):e76340. doi:10.1371/journal.pone.007634024130769
   PubMed Web of Science ®Google Scholar
• Raha P, Thomas S, Thurn KT, Park J, Munster PN. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Res. 2015;17(1):26. doi:10.1186/s13058-015-0533-z25848915
   PubMedGoogle Scholar
• Grabarska A, Łuszczki JJ, Nowosadzka E, et al. Histone deacetylase inhibitor SAHA as potential targeted therapy agent for larynx cancer cells. J Cancer. 2017;8(1):19–28. doi:10.7150/jca.1665528123594
   PubMed Web of Science ®Google Scholar
• Gumbarewicz E, Luszczki JJ, Wawruszak A, et al. Isobolographic analysis demonstrates additive effect of cisplatin and HDIs combined treatment augmenting their anti-cancer activity in lung cancer cell lines. Am J Cancer Res. 2016;6(12):2831–2845. http://www.ncbi.nlm.nih.gov/pubmed/28042503. Accessed February 7, 2019.28042503
   PubMed Web of Science ®Google Scholar
• Heers H, Stanislaw J, Harrelson J, Lee MW. Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer. Eur J Pharmacol. 2018;835:61–74. doi:10.1016/j.ejphar.2018.07.05730075223
   PubMed Web of Science ®Google Scholar
• Wu S, Luo Z, Yu P-J, Xie H, He Y-W. Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial mesenchymal transition of triple negative breast cancer cells via HDAC8/FOXA1 signals. Biol Chem. 2016;397(1):75–83. doi:10.1515/hsz-2015-021526431101
   PubMed Web of Science ®Google Scholar
• Debeb BG, Lacerda L, Xu W, et al. Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/β-catenin signaling. Stem Cells. 2012;30(11):2366–2377. doi:10.1002/stem.121922961641
   PubMed Web of Science ®Google Scholar
• Maret D, Gruzglin E, Sadr MS, et al. Surface expression of precursor N-cadherin promotes tumor cell invasion. Neoplasia. 2010;12(12):1066–1080. doi:10.1593/neo.1095421170270
   PubMed Web of Science ®Google Scholar
• Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol. 2000;148(4):779–790. doi:10.1083/JCB.148.4.77910684258
   PubMed Web of Science ®Google Scholar
• Srivastava RK, Kurzrock R, Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther. 2010;9(12):3254–3266. doi:10.1158/1535-7163.MCT-10-058221041383
   PubMed Web of Science ®Google Scholar
• Nelson ER, Li S, Kennedy M, et al. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface. Oncotarget. 2016;7(51):84030–84042. doi:10.18632/oncotarget.1276727768598
   PubMedGoogle Scholar
• Hulit J, Suyama K, Chung S, et al. N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Res. 2007;67(7):3106–3116. doi:10.1158/0008-5472.CAN-06-340117409417
   PubMed Web of Science ®Google Scholar
• Qian X, Anzovino A, Kim S, et al. N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties. Oncogene. 2014;33(26):3411–3421. doi:10.1038/onc.2013.31023975425
   PubMed Web of Science ®Google Scholar
• Tramm T, Kyndi M, Sørensen FB, Overgaard J, Alsner J. Influence of intra-tumoral heterogeneity on the evaluation of BCL2, E-cadherin, EGFR, EMMPRIN, and Ki-67 expression in tissue microarrays from breast cancer. Acta Oncol (Madr). 2018;57(1):102–106. doi:10.1080/0284186X.2017.1404128
   PubMed Web of Science ®Google Scholar
• Hugo HJ, Gunasinghe NPAD, Hollier BG, et al. Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin. Breast Cancer Res. 2017;19(1):86. doi:10.1186/s13058-017-0880-z28750639
   PubMedGoogle Scholar
• Li G-F, Qian T-L, Li G-S, et al. Sodium valproate inhibits MDA-MB-231 breast cancer cell migration by upregulating NM23H1 expression. Genet Mol Res. 2012;11(1):77–86. doi:10.4238/2012.January.13.122290468
   PubMed Web of Science ®Google Scholar
• Butti R, Gunasekaran VP, Kumar TVS, Banerjee P, Kundu GC. Breast cancer stem cells: biology and therapeutic implications. Int J Biochem Cell Biol. 2019;107:38–52. doi:10.1016/j.biocel.2018.12.00130529656
   PubMed Web of Science ®Google Scholar